#78 – New Therapies in HIV: The Long Road to Long-acting Antiretrovirals - Are We There Yet?
Breakpoints
00:00
The Importance of Lena Capaver in HIV Treatment
The population for whom lena capaver and embolizumab have been approved is very small. We're talking about less than 1% of the HIV population in the United States. They stand out in our minds because they're very difficult to manage. As a result, there's very little use of ableizumab and lena capavers at this point.
Transcript
Play full episode
